3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Recruiting
1
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Head & Neck
1
Genitourinary
1
Gastrointestinal
1
Conditions
Melanoma
7
Neoplasms
4
Advanced Cancer
4
Lymphoma, Non-Hodgkin
3
Carcinoma, Non-Small-Cell Lung
3
Carcinoma, Hepatocellular
3
Lymphoma, Large B-Cell, Diffuse
2
Liver Neoplasms
2
Hodgkin Disease
2
Various Advanced Cancer
1
Uveal Melanoma
1
Stomach Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Skin Neoplasms
1
Recurrence
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Neoplasms by Site
1
Microsatellite Unstable Colorectal Cancer
1
Melanoma, Cutaneous Malignant
1
Lymphoma, T-Cell, Peripheral
1
Lymphoma, Large-Cell, Anaplastic
1
Lymphoma, Follicular
1
Lymphoma, Extranodal NK-T-Cell
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Hematologic Neoplasms
1
Colorectal Neoplasms
1
Carcinoma, Transitional Cell
1
Carcinoma, Renal Cell
1
Burkitt Lymphoma
1
Advanced Solid Tumors
1
Interventions
pembrolizumab
51
Nivolumab
27
Gemcitabine
23
atezolizumab
19
Cisplatin
18
Carboplatin
18
enfortumab vedotin
15
avelumab
15
Mitomycin
14
Docetaxel
8
Ipilimumab
7
Paclitaxel
6
Injections
5
Cyclophosphamide
5
vinflunine
4
toripalimab
4
tislelizumab
4
lenvatinib
4
fludarabine
4
epacadostat
4
Pemetrexed
4
130-nm albumin-bound paclitaxel
4
sacituzumab govitecan
3
disitamab vedotin
3
Rogaratinib
3
Interleukin-2
3
ALT-803
3
vofatamab
2
valrubicin
2
rucaparib
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Carcinoma, Transitional Cell
×
relatlimab
×
Clear all
NCT05176483
2026-05-27
STELLAR-002
Exelixis
Phase 1
Recruiting
1,314 enrolled